ITPRID2

Summary

ITPRID2 (ITPR interacting domain containing 2, HGNC:11319) is a protein-coding gene on chromosome 2q31.3, encoding Protein ITPRID2 (P28290).

Enables actin filament binding activity. Located in cytosol; nucleoplasm; and plasma membrane.

Source: NCBI Gene 6744 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 235 total
• MANE Select transcript: NM_001130445

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11319
Approved symbol	ITPRID2
Name	ITPR interacting domain containing 2
Location	2q31.3
Locus type	gene with protein product
Status	Approved
Aliases	CS-1, SPAG13, KRAP, KIAA1927
Ensembl gene	ENSG00000138434
Ensembl biotype	protein_coding
OMIM	118990
Entrez	6744

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 5 protein_coding, 4 protein_coding_CDS_not_defined, 3 nonsense_mediated_decay, 3 retained_intron

ENST00000320370, ENST00000409001, ENST00000409136, ENST00000416081, ENST00000431877, ENST00000440623, ENST00000451836, ENST00000454579, ENST00000467172, ENST00000470129, ENST00000470654, ENST00000480753, ENST00000491720, ENST00000491866, ENST00000495248

RefSeq mRNA: 5 — MANE Select: NM_001130445 NM_001130445, NM_001287503, NM_001287504, NM_001287505, NM_006751

CCDS: CCDS2284, CCDS46467, CCDS74611

Canonical transcript exons

ENST00000431877 — 18 exons

Exon	Start	End
ENSE00001856802	181891730	181892277
ENSE00003470274	181892615	181892660
ENSE00003478432	181899014	181899112
ENSE00003481058	181915216	181916427
ENSE00003484965	181909899	181909971
ENSE00003509369	181896030	181896079
ENSE00003540610	181900696	181900904
ENSE00003550859	181918755	181918882
ENSE00003553870	181919296	181919446
ENSE00003585470	181928161	181928278
ENSE00003591649	181918598	181918675
ENSE00003595199	181898880	181898919
ENSE00003608086	181896908	181896964
ENSE00003632928	181901766	181902466
ENSE00003641110	181920597	181920662
ENSE00003656704	181913845	181913933
ENSE00003659149	181921948	181922412
ENSE00003682798	181929561	181930738

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 98.90.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 42.4994 / max 461.1191, expressed in 1817 samples.

FANTOM5 promoters (18 alternative TSS)

Promoter ID	TPM avg	Samples expressed
24022	22.1675	1781
24020	3.4297	1381
24017	3.0739	1373
24019	3.0260	1378
24029	2.8586	1065
24018	2.5707	1312
24023	1.4196	654
24028	1.2383	605
24021	0.7018	428
24024	0.6817	342

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	98.90	gold quality
tibial nerve	UBERON:0001323	98.34	gold quality
stromal cell of endometrium	CL:0002255	98.23	gold quality
colonic epithelium	UBERON:0000397	98.16	gold quality
sural nerve	UBERON:0015488	98.03	gold quality
upper leg skin	UBERON:0004262	97.64	gold quality
rectum	UBERON:0001052	97.57	gold quality
hair follicle	UBERON:0002073	97.52	gold quality
skin of leg	UBERON:0001511	97.47	gold quality
zone of skin	UBERON:0000014	97.37	gold quality
pancreas	UBERON:0001264	97.32	gold quality
skin of abdomen	UBERON:0001416	97.31	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.30	gold quality
endothelial cell	CL:0000115	97.17	gold quality
cerebellar hemisphere	UBERON:0002245	97.14	gold quality
cerebellar cortex	UBERON:0002129	97.04	gold quality
mucosa of sigmoid colon	UBERON:0004993	96.98	gold quality
right lung	UBERON:0002167	96.93	gold quality
gall bladder	UBERON:0002110	96.85	gold quality
colonic mucosa	UBERON:0000317	96.84	gold quality
skin of hip	UBERON:0001554	96.81	gold quality
lower lobe of lung	UBERON:0008949	96.65	gold quality
trigeminal ganglion	UBERON:0001675	96.63	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.55	gold quality
adrenal tissue	UBERON:0018303	96.52	gold quality
jejunal mucosa	UBERON:0000399	96.50	gold quality
calcaneal tendon	UBERON:0003701	96.44	gold quality
medial globus pallidus	UBERON:0002477	96.38	gold quality
cerebellum	UBERON:0002037	96.28	gold quality
choroid plexus epithelium	UBERON:0003911	96.27	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-81547	yes	20.94
E-CURD-114	yes	11.46
E-MTAB-10137	no	3.81
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ESR1

miRNA regulators (miRDB)

128 targeting ITPRID2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502

Literature-anchored findings (GeneRIF, showing 12)

• localized as a membrane-bound form with extracellular regions; results suggested KRAP might be involved in the regulation of filamentous actin and signals from the outside of the cells (PMID:14673706)
• results suggested that KRAP might be a cytoskeleton-associated protein involving the structural integrity and/or signal transductions in human cancers. (PMID:17934691)
• KRAP is involved in the proper regulation of IP3R-mediated Ca2+ release. (PMID:21457704)
• the critical region of KRAP protein for the regulation of IP(3)R was determined. (PMID:21501587)
• the predicted coiled-coil region & the region adjacent to the coiled-coil region of the carboxyl-terminus of KRAP may be crucial for its interaction with the cytoskeleton or directional targeting toward the apical pole in polarized epithelial cells (PMID:21873152)
• phosphorylation at Ser92 of the sperm-specific antigen 2 (SSFA2)[phospho-SSFA2 (pS92)], was related to poor prognosis. (PMID:26947549)
• These result reveals us that SSFA2 may act as oncogene to promote the progression of glioma (PMID:30712887)
• KRAP tethers IP3 receptors to actin and licenses them to evoke cytosolic Ca(2+) signals. (PMID:34301929)
• Circular RNA UBR1 promotes the proliferation, migration, and invasion but represses apoptosis of lung cancer cells via modulating microRNA-545-5p/SSFA2 axis. (PMID:34787049)
• KRAP is required for diffuse and punctate IP3-mediated Ca(2+) liberation and determines the number of functional IP3R channels within clusters. (PMID:36030740)
• IP3R1 dysregulation via mir-200c-3p/SSFA2 axis contributes to taxol resistance in head and neck cancer. (PMID:38642666)
• KRAP regulates mitochondrial Ca2+ uptake by licensing IP3 receptor activity and stabilizing ER-mitochondrial junctions. (PMID:38786982)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	itprid2	ENSDARG00000038938
mus_musculus	Itprid2	ENSMUSG00000027007
rattus_norvegicus	Itprid2	ENSRNOG00000005865

Paralogs (2): TESPA1 (ENSG00000135426), ITPRID1 (ENSG00000180347)

Protein

Protein identifiers

Protein ITPRID2 — P28290 (reviewed: P28290)

Alternative names: Cleavage signal-1 protein, ITPR-interacting domain-containing protein 2, Ki-ras-induced actin-interacting protein, Sperm-specific antigen 2

All UniProt accessions (5): E7EUL7, E9PHV5, F2Z295, H7BZ26, P28290

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasm.

Tissue specificity. Strongly expressed in pancreas and testis. Present in colon cancer cells (at protein level).

Post-translational modifications. A 33 kDa peptide corresponding to the C-terminus of this protein is found in the testis and seems to be cleaved into 2 peptides of 14 kDa and 18 kDa found on the surface of mature sperm cells. This sperm surface antigen may be involved in some step of early cleavage of the fertilized oocyte.

Induction. Up-regulated by activated KRAS.

Isoforms (3)

UniProt ID	Names	Canonical?
P28290-1	1	yes
P28290-2	2
P28290-3	3

RefSeq proteins (4): NP_001123917, NP_001274432, NP_001274433, NP_006742 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029325	ITPR-bd	Domain
IPR029326	SSFA2_C	Domain
IPR043444	TESPA1-like	Family

Pfam: PF14722, PF14723

UniProt features (60 total): modified residue 26, sequence conflict 9, compositionally biased region 8, region of interest 6, sequence variant 4, splice variant 3, cross-link 2, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P28290-F1	50.96	0.05

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (28): 87, 92, 111, 209, 270, 330, 466, 644, 668, 737, 739, 746, 759, 767, 803, 869, 902, 1040, 1055, 1060 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 207 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, HORIUCHI_WTAP_TARGETS_DN, WANG_CLIM2_TARGETS_UP, GRUETZMANN_PANCREATIC_CANCER_DN, YAGI_AML_WITH_INV_16_TRANSLOCATION, BILD_SRC_ONCOGENIC_SIGNATURE, AGGCACT_MIR5153P, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, TGTGTGA_MIR377, HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN, GOMF_ACTIN_BINDING

GO Biological Process (0):

GO Molecular Function (4): signaling receptor binding (GO:0005102), actin filament binding (GO:0051015), actin binding (GO:0003779), protein binding (GO:0005515)

GO Cellular Component (4): nucleoplasm (GO:0005654), cytosol (GO:0005829), plasma membrane (GO:0005886), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein binding	1
actin binding	1
protein-containing complex binding	1
cytoskeletal protein binding	1
binding	1
nuclear lumen	1
cytoplasm	1
membrane	1
cell periphery	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

728 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ITPRID2	COBL	O75128	863
ITPRID2	WAS	P42768	604
ITPRID2	APPBP2	Q92624	518
ITPRID2	IZUMO4	Q1ZYL8	497
ITPRID2	TEX2	Q8IWB9	469
ITPRID2	NWD1	Q149M9	433
ITPRID2	GRB10	Q13322	423
ITPRID2	PJVK	Q0ZLH3	406
ITPRID2	HSD17B14	Q9BPX1	397
ITPRID2	VANGL2	Q9ULK5	389
ITPRID2	INTS11	Q5TA45	361
ITPRID2	SPAG7	O75391	357
ITPRID2	BEND6	Q5SZJ8	350
ITPRID2	SPAG5	Q96R06	347
ITPRID2	INTS1	Q8N201	346

IntAct

151 interactions, top by confidence:

A	B	Type	Score
CSNK1A1	FAM83G	psi-mi:“MI:0914”(association)	0.900
KIF24	CCP110	psi-mi:“MI:0914”(association)	0.810
ITPRID2	YWHAQ	psi-mi:“MI:0915”(physical association)	0.790
L3MBTL2	E2F6	psi-mi:“MI:0914”(association)	0.730
ITPRID2	SGF29	psi-mi:“MI:0915”(physical association)	0.710
YWHAG	BLTP3B	psi-mi:“MI:2364”(proximity)	0.640
TSG101	ITPRID2	psi-mi:“MI:0407”(direct interaction)	0.620
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAB	BLTP3B	psi-mi:“MI:2364”(proximity)	0.610
YWHAH	BLTP3B	psi-mi:“MI:2364”(proximity)	0.570
TFDP3	E2F3	psi-mi:“MI:0914”(association)	0.530
TAFA4	NRP1	psi-mi:“MI:0914”(association)	0.530
FGL2	PCNT	psi-mi:“MI:0914”(association)	0.530
ITPRID2	PIGR	psi-mi:“MI:0914”(association)	0.530
ARC	FER	psi-mi:“MI:0914”(association)	0.530
BBOX1	ITPRID2	psi-mi:“MI:0914”(association)	0.530
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
STX11	EXOC5	psi-mi:“MI:0914”(association)	0.530
ITPRID2	CBL	psi-mi:“MI:0914”(association)	0.530
SGF29	MATN2	psi-mi:“MI:0914”(association)	0.530
YWHAZ	ITPRID2	psi-mi:“MI:0915”(physical association)	0.520
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480

BioGRID (204): SSFA2 (Affinity Capture-MS), SSFA2 (Affinity Capture-MS), CBL (Affinity Capture-MS), FKBP15 (Affinity Capture-MS), CCDC101 (Affinity Capture-MS), PIGR (Affinity Capture-MS), PCM1 (Affinity Capture-MS), IGHA2 (Affinity Capture-MS), IGHA1 (Affinity Capture-MS), VPS33B (Affinity Capture-MS), SSFA2 (Affinity Capture-MS), SSFA2 (Affinity Capture-MS), SSFA2 (Affinity Capture-MS), SSFA2 (Affinity Capture-MS), SSFA2 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GVS7, A2CE83, A2VDU1, A5D992, A8KBE0, O43597, O43609, O43610, P28290, Q02223, Q08AD1, Q08E39, Q14CH0, Q1L0X2, Q2PFN5, Q2TBG9, Q3UUD2, Q4R815, Q5R959, Q5RGQ8, Q5TB30, Q66H35, Q6AYK4, Q6DD45, Q6GPM0, Q6NRB7, Q6P995, Q6PEM6, Q6ZUJ8, Q7ZX27, Q866R9, Q86VY9, Q8BGN6, Q8C3K5, Q8C817, Q8IYD9, Q8N957, Q96HH4, Q9BZD6, Q9C004

Diamond homologs: A2RU30, P28290, Q14B48, Q3U132, Q6ZRS4, Q922B9, Q5REU9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 155 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	52.2×	5e-09
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	46.1×	8e-09
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	46.1×	8e-09
Activation of BH3-only proteins	7	34.1×	7e-08
RHO GTPases activate PKNs	9	28.0×	5e-09
Ras activation upon Ca2+ influx through NMDA receptor	5	28.0×	2e-05
Unblocking of NMDA receptors, glutamate binding and activation	5	26.7×	2e-05
RHO GTPases activate PAKs	5	26.7×	2e-05

GO biological processes:

GO term	Partners	Fold	FDR
regulation of neuronal synaptic plasticity	5	25.1×	5e-04
substantia nigra development	6	16.4×	5e-04
long-term synaptic potentiation	7	14.7×	4e-04
protein targeting	5	13.7×	5e-03
intracellular protein localization	10	7.8×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

235 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	203
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3078 predictions. Top by Δscore:

Variant	Effect	Δscore
2:181892214:G:GT	donor_gain	1.0000
2:181892223:G:GT	donor_gain	1.0000
2:181892232:G:GT	donor_gain	1.0000
2:181892235:G:GT	donor_gain	1.0000
2:181892275:GAG:G	donor_gain	1.0000
2:181892275:GAGG:G	donor_loss	1.0000
2:181892278:GTC:G	donor_loss	1.0000
2:181892607:A:AG	acceptor_gain	1.0000
2:181896028:A:AG	acceptor_gain	1.0000
2:181896029:G:GG	acceptor_gain	1.0000
2:181896960:TGAAG:T	donor_loss	1.0000
2:181896961:GAAGG:G	donor_loss	1.0000
2:181896962:AAGGT:A	donor_loss	1.0000
2:181896964:GGT:G	donor_loss	1.0000
2:181896965:G:A	donor_loss	1.0000
2:181896966:T:G	donor_loss	1.0000
2:181898872:A:AG	acceptor_gain	1.0000
2:181898873:C:G	acceptor_gain	1.0000
2:181898878:A:AG	acceptor_gain	1.0000
2:181898879:G:GG	acceptor_gain	1.0000
2:181898879:GC:G	acceptor_gain	1.0000
2:181899012:A:AG	acceptor_gain	1.0000
2:181899013:G:GG	acceptor_gain	1.0000
2:181899013:GCA:G	acceptor_gain	1.0000
2:181899013:GCAAT:G	acceptor_gain	1.0000
2:181900694:A:AG	acceptor_gain	1.0000
2:181900694:AGT:A	acceptor_gain	1.0000
2:181900695:G:GA	acceptor_gain	1.0000
2:181900695:GT:G	acceptor_gain	1.0000
2:181900695:GTG:G	acceptor_gain	1.0000

AlphaMissense

8250 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:181892644:T:A	W81R	1.000
2:181892644:T:C	W81R	1.000
2:181892646:G:C	W81C	1.000
2:181892646:G:T	W81C	1.000
2:181892648:T:C	L82P	1.000
2:181900743:T:A	L184H	1.000
2:181900743:T:C	L184P	1.000
2:181900752:T:C	L187P	1.000
2:181900757:T:C	F189L	1.000
2:181900758:T:C	F189S	1.000
2:181900759:T:A	F189L	1.000
2:181900759:T:G	F189L	1.000
2:181901771:T:C	F240L	1.000
2:181901772:T:C	F240S	1.000
2:181901773:T:A	F240L	1.000
2:181901773:T:G	F240L	1.000
2:181901790:T:C	L246P	1.000
2:181901801:G:C	A250P	1.000
2:181901802:C:A	A250D	1.000
2:181901807:G:C	A252P	1.000
2:181892137:G:C	R24T	0.999
2:181892138:G:C	R24S	0.999
2:181892138:G:T	R24S	0.999
2:181892145:T:A	W27R	0.999
2:181892145:T:C	W27R	0.999
2:181892147:G:C	W27C	0.999
2:181892147:G:T	W27C	0.999
2:181900707:T:C	L172S	0.999
2:181900710:T:C	L173S	0.999
2:181900716:T:C	L175P	0.999

dbSNP variants (sampled 300 via entrez): RS1000100482 (2:181900724 G>A), RS1000171421 (2:181927464 T>G), RS1000267058 (2:181901249 C>T), RS1000308719 (2:181918150 C>G,T), RS1000413491 (2:181892855 C>T), RS1000484729 (2:181924474 G>C), RS1000598663 (2:181918289 T>A), RS1000601405 (2:181902791 A>C), RS1000614762 (2:181894253 T>G), RS1000734179 (2:181905526 T>A), RS1000736220 (2:181890379 T>C), RS1000812176 (2:181930882 A>T), RS1000827195 (2:181926449 C>A,T), RS1000842066 (2:181928538 G>A), RS1000952040 (2:181892180 G>A)

Disease associations

OMIM: gene MIM:118990 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases methylation	6
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	affects methylation, decreases expression, increases abundance, increases expression	3
Air Pollutants	increases expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	affects sumoylation	1
bisphenol A	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
arsenite	decreases reaction, affects binding	1
nickel sulfate	increases expression	1
coumarin	decreases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
2-palmitoylglycerol	increases expression	1
monomethylarsonous acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
torcetrapib	increases expression	1
ICG 001	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Sunitinib	increases expression	1
Zoledronic Acid	decreases expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	affects expression	1
Leflunomide	increases expression	1
Arsenic	decreases expression, increases abundance	1
Vehicle Emissions	decreases reaction, increases expression	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery